Determining the optimal dry powder adenosine provocation test to assess small airways disease

Completed

• Conditions: asthma; inflammation of the airways; 10006436

• Registration Number: NL-OMON38368
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

• A docter*s diagnosis of asthma
• Age: 18-65 years
• PC20 methacholine-bromide <= 4.9mg/ml
• Non-smoker

Exclusion Criteria

• Steroid use 4 weeks before entry into the baseline period
• Recent exacerbation asthma (<2 months) or upper respiration tract infection (<2 weeks)
• Severe airway obstruction at baseline, FEV1pred < 50%or < 1.2L
• Diagnosis of COPD or any other pulmonary disease that could influence the study results as judged by the investigator
• Pregnancy or lactating women

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The major endpoint of the study is the change in small airways resistance<br /><br>during the provocation tests, clarified as R5-R20 measured with IOS (impulse<br /><br>oscillometry). Other endpoints of this study are the decline in FVC at 20% fall<br /><br>in FEV1, and the PD20/PC20 values.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Other endpoints of this study are the decline in FVC at 20% fall in FEV1, and<br /><br>the PD20/PC20 values.</p><br>